Part 1: Cell-mediated immunity critical to vaccine performance
What is “cell-mediated immunity” and how does it affect vaccine performance? Are two PCV2 genotypes necessarily better than one? And what does a monster from Greek mythology have to do with building a better vaccine?
Part 1: Cell-mediated immunity critical to vaccine performance
What is “cell-mediated immunity” and how does it affect vaccine performance? Are two PCV2 genotypes necessarily better than one? And what does a monster from Greek mythology have to do with building a better vaccine?